Synonym
Nutlin-2; Nutlin 2; Nutlin2;
IUPAC/Chemical Name
cis-[4,5-Bis(4-bromophenyl)-2-(2-ethoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-[4-(2-hydroxyethyl)piperazin-1-yl]methanone
InChi Key
PVRYEWOXWGDQHA-WDYNHAJCSA-N
InChi Code
InChI=1S/C31H34Br2N4O4/c1-3-41-27-20-25(40-2)12-13-26(27)30-34-28(21-4-8-23(32)9-5-21)29(22-6-10-24(33)11-7-22)37(30)31(39)36-16-14-35(15-17-36)18-19-38/h4-13,20,28-29,38H,3,14-19H2,1-2H3/t28-,29+/m1/s1
SMILES Code
O=C(N1[C@@H](C2=CC=C(Br)C=C2)[C@@H](C3=CC=C(Br)C=C3)N=C1C4=CC=C(OC)C=C4OCC)N5CCN(CCO)CC5
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
686.44
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Zhang B, Golding BT, Hardcastle IR. Small-molecule MDM2-p53 inhibitors: recent advances. Future Med Chem. 2015;7(5):631-45. doi: 10.4155/fmc.15.13. Review. PubMed PMID: 25921402.
2: Anil B, Riedinger C, Endicott JA, Noble ME. The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant. Acta Crystallogr D Biol Crystallogr. 2013 Aug;69(Pt 8):1358-66. doi: 10.1107/S0907444913004459. Epub 2013 Jul 13. PubMed PMID: 23897459.
3: ElSawy KM, Verma CS, Joseph TL, Lane DP, Twarock R, Caves LS. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study. Cell Cycle. 2013 Feb 1;12(3):394-404. doi: 10.4161/cc.23511. Epub 2013 Jan 16. PubMed PMID: 23324352; PubMed Central PMCID: PMC3587439.
4: Fuller JC, Jackson RM, Edwards TA, Wilson AJ, Shirts MR. Modeling of arylamide helix mimetics in the p53 peptide binding site of hDM2 suggests parallel and anti-parallel conformations are both stable. PLoS One. 2012;7(8):e43253. doi: 10.1371/journal.pone.0043253. Epub 2012 Aug 20. PubMed PMID: 22916232; PubMed Central PMCID: PMC3423354.
5: Rufini A, Melino G. Cell death pathology: the war against cancer. Biochem Biophys Res Commun. 2011 Oct 28;414(3):445-50. doi: 10.1016/j.bbrc.2011.09.110. Epub 2011 Sep 28. Review. PubMed PMID: 21971555.
6: Popowicz GM, Dömling A, Holak TA. The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed Engl. 2011 Mar 14;50(12):2680-8. doi: 10.1002/anie.201003863. Epub 2011 Feb 21. Review. PubMed PMID: 21341346; PubMed Central PMCID: PMC3113661.
7: Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma CS. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle. 2010 Mar 15;9(6):1167-81. Epub 2010 Mar 15. PubMed PMID: 20190571.
8: Vassilev LT. p53 Activation by small molecules: application in oncology. J Med Chem. 2005 Jul 14;48(14):4491-9. Review. PubMed PMID: 15999986.
9: Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004 Feb 6;303(5659):844-8. Epub 2004 Jan 2. PubMed PMID: 14704432.
